We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Federal Circuit Upholds Pfizer Patent, Blocks Generic Xalatan

Law360 (August 14, 2005, 12:00 AM EDT) -- Pfizer Inc.’s glaucoma drug Xalatan is off limits to generics manufacturer Par Pharmaceutical Inc., following a decision in Pfizer’s favor by the U.S. Court of Appeals for the Federal Circuit.

The initial complaint was filed in December 2001 in the U.S. District Court for New Jersey after Par announced its plans to create a generic version of Xalatan.

Par’s abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration (FDA) claimed two key patents behind Xalatan invalid, alleging inequitable conduct during the patent application...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.